Multiple endocrine neoplasia type 2 historical perspective: Difference between revisions
Usama Talib (talk | contribs) |
No edit summary |
||
Line 10: | Line 10: | ||
<br> | <br> | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
|+'''''MEN II Historical Background''''' | |+'''''MEN II Historical Background''''' | ||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Years}} | ! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Years}} | ||
Line 18: | Line 18: | ||
! style="background: #DCDCDC;" |1954 | ! style="background: #DCDCDC;" |1954 | ||
! style="background: #F5F5F5;" |Wermer | ! style="background: #F5F5F5;" |Wermer | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Reported that [[syndrome]] was transmitted as a dominant trait | | style="padding: 5px 5px; background: #F5F5F5;" |Reported that [[syndrome]] was transmitted as a [[dominant]] trait | ||
|- | |- | ||
! style="background: #DCDCDC;" |1959 | ! style="background: #DCDCDC;" |1959 | ||
! style="background: #F5F5F5;" |Hazard | ! style="background: #F5F5F5;" |Hazard | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Described medullary (solid) | | style="padding: 5px 5px; background: #F5F5F5;" |Described [[Medullary thyroid carcinoma|medullary (solid) thyroid carcinoma]] | ||
|- | |- | ||
! style="background: #DCDCDC;" |1961 | ! style="background: #DCDCDC;" |1961 | ||
Line 34: | Line 34: | ||
! style="background: #DCDCDC;" |1966 | ! style="background: #DCDCDC;" |1966 | ||
! style="background: #F5F5F5;" |Williams | ! style="background: #F5F5F5;" |Williams | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case of a patient with combination of mucosal neuromas, [[pheochromocytoma]], and [[medullary thyroid carcinoma]] | | style="padding: 5px 5px; background: #F5F5F5;" |Reported a case of a patient with combination of mucosal [[Neuroma|neuromas]], [[pheochromocytoma]], and [[medullary thyroid carcinoma]] | ||
|- | |- | ||
! style="background: #DCDCDC;" | ! rowspan="2" style="background: #DCDCDC;" |1968 | ||
! style="background: #F5F5F5;" |Steiner | ! style="background: #F5F5F5;" |Steiner | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of [[endocrine]] [[tumor]]s and proposed the terms '[[Wermer syndrome]]' for multiple endocrine neoplasia type 1 and '[[Sipple syndrome]]' for multiple endocrine neoplasia type 2 | | style="padding: 5px 5px; background: #F5F5F5;" |Introduced the term "[[multiple endocrine neoplasia]]" ([[Multiple endocrine neoplasia|MEN]]) to describe disorders featuring combinations of [[endocrine]] [[tumor]]s and proposed the terms '[[Wermer syndrome]]' for [[multiple endocrine neoplasia type 1]] and '[[Sipple syndrome]]' for [[multiple endocrine neoplasia type 2]] | ||
|- | |- | ||
! style="background: #F5F5F5;" |Meyer and Abdel-Bari | ! style="background: #F5F5F5;" |Meyer and Abdel-Bari | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Suggested that medullary carcinoma produces thyrocalcitonin from [[parafollicular cell]]s | | style="padding: 5px 5px; background: #F5F5F5;" |Suggested that [[medullary carcinoma]] produces [[Calcitonon|thyrocalcitonin]] from [[parafollicular cell]]s | ||
|- | |- | ||
! style="background: #DCDCDC;" |1970 | ! style="background: #DCDCDC;" |1970 | ||
Line 49: | Line 49: | ||
! style="background: #DCDCDC;" |1974 | ! style="background: #DCDCDC;" |1974 | ||
! style="background: #F5F5F5;" |Sizemore | ! style="background: #F5F5F5;" |Sizemore | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Showed that the multiple endocrine neoplasia type 2 category included two groups of patients with medullary | | style="padding: 5px 5px; background: #F5F5F5;" |Showed that the multiple endocrine neoplasia type 2 category included two groups of patients with [[medullary thyroid cancer]] and [[pheochromocytoma]]: one with [[parathyroid]] [[disease]] and a normal appearance (multiple endocrine neoplasia type 2A) and the other without [[parathyroid]] [[disease]] but with mucosal [[Neuroma|neuromas]] and mesodermal abnormalities (multiple endocrine neoplasia type 2B) | ||
|- | |- | ||
! style="background: #DCDCDC;" | ! rowspan="2" style="background: #DCDCDC;" |1978 | ||
! style="background: #F5F5F5;" |Hamilton | ! style="background: #F5F5F5;" |Hamilton | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Reported a case of [[Zollinger-Ellison syndrome]] in multiple endocrine hyperplasia type 2 | | style="padding: 5px 5px; background: #F5F5F5;" |Reported a case of [[Zollinger-Ellison syndrome]] in multiple endocrine hyperplasia type 2 | ||
|- | |- | ||
! style="background: #F5F5F5;" |Cameron | ! style="background: #F5F5F5;" |Cameron | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Suggested that medullary carcinoma produces thyrocalcitonin from [[parafollicular cell]]s<ref name="pmid26873">{{cite journal| author=Cameron D, Spiro HM, Landsberg L| title=Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II. | journal=N Engl J Med | year= 1978 | volume= 299 | issue= 3 | pages= 152-3 | pmid=26873 | doi=10.1056/NEJM197807202990315 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26873 }} </ref> | | style="padding: 5px 5px; background: #F5F5F5;" |Suggested that [[Medullary carcinoma of the thyroid|medullary carcinoma]] produces [[Calcitonin|thyrocalcitonin]] from [[parafollicular cell]]s<ref name="pmid26873">{{cite journal| author=Cameron D, Spiro HM, Landsberg L| title=Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II. | journal=N Engl J Med | year= 1978 | volume= 299 | issue= 3 | pages= 152-3 | pmid=26873 | doi=10.1056/NEJM197807202990315 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26873 }} </ref> | ||
|- | |- | ||
! style="background: #DCDCDC;" |1980 | ! style="background: #DCDCDC;" |1980 | ||
! style="background: #F5F5F5;" |Le Marec | ! style="background: #F5F5F5;" |Le Marec | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Described a case of congential megacolon in Sipple syndrome<ref name="pmid7276917">{{cite journal| author=Le Marec B, Roussey M, Cornec A, Calmettes C, Kerisit J, Allanic H| title=[Thyroid cancer with amyloid stroma, Sipple's syndrome, congenital megacolon with plexus hyperplasia: one and the same dominant autosomal disease with complete penetrance]. | journal=J Genet Hum | year= 1981 | volume= 28 | issue= 5 | pages= 169-74 | pmid=7276917 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7276917 }} </ref> | | style="padding: 5px 5px; background: #F5F5F5;" |Described a case of congential [[megacolon]] in [[Sipple syndrome]]<ref name="pmid7276917">{{cite journal| author=Le Marec B, Roussey M, Cornec A, Calmettes C, Kerisit J, Allanic H| title=[Thyroid cancer with amyloid stroma, Sipple's syndrome, congenital megacolon with plexus hyperplasia: one and the same dominant autosomal disease with complete penetrance]. | journal=J Genet Hum | year= 1981 | volume= 28 | issue= 5 | pages= 169-74 | pmid=7276917 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7276917 }} </ref> | ||
|- | |- | ||
! style="background: #DCDCDC;" |1989 | ! style="background: #DCDCDC;" |1989 | ||
! style="background: #F5F5F5;" |Sobol | ! style="background: #F5F5F5;" |Sobol | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Proposed that restriction fragment length polymerase is useful in predicting the carrier state of multiple endocrine neoplasia syndrome | | style="padding: 5px 5px; background: #F5F5F5;" |Proposed that restriction fragment length polymerase is useful in predicting the carrier state of [[multiple endocrine neoplasia syndrome]] | ||
|- | |- | ||
! style="background: #DCDCDC;" |1993 | ! style="background: #DCDCDC;" |1993 | ||
! style="background: #F5F5F5;" | | ! style="background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |RET germline mutations were recognized as the causative molecular alterations in multiple endocrine neoplasia type 2 syndromes | | style="padding: 5px 5px; background: #F5F5F5;" |[[RET gene|RET]] germline mutations were recognized as the causative molecular alterations in multiple endocrine neoplasia type 2 syndromes | ||
|- | |- | ||
! style="background: #DCDCDC;" |1998 | ! style="background: #DCDCDC;" |1998 | ||
! style="background: #F5F5F5;" | | ! style="background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |''MEN1'' gene was cloned<ref name="Guru1998">Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. ''J Intern Med'' 243(6) 433-9</ref> | | style="padding: 5px 5px; background: #F5F5F5;" |[[MEN1|''MEN1'' gene]] was cloned<ref name="Guru1998">Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. ''J Intern Med'' 243(6) 433-9</ref> | ||
|- | |- | ||
! style="background: #DCDCDC;" | | ! style="background: #DCDCDC;" | |
Revision as of 20:46, 18 October 2017
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 historical perspective On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective |
FDA on Multiple endocrine neoplasia type 2 historical perspective |
CDC on Multiple endocrine neoplasia type 2 historical perspective |
Multiple endocrine neoplasia type 2 historical perspective in the news |
Blogs on Multiple endocrine neoplasia type 2 historical perspective |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Multiple endocrine neoplasia type 2 was first described by Dr. John H. Sipple, an American physician, in 1961 by reporting a case of a patient with pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenoma.
Historical Perspective
The historical background of multiple endocrine neoplasia type 2 is given in the table below:
Years | Scientist | Contribution |
---|---|---|
1954 | Wermer | Reported that syndrome was transmitted as a dominant trait |
1959 | Hazard | Described medullary (solid) thyroid carcinoma |
1961 | Sipple | Described a case of a patient with pheochromocytoma, medullary thyroid carcinoma, and parathyroid adenoma. It was based on a case he saw when he was in 3rd year medical residency about a person with intracranial bleed and fluctuating blood pressure. His autopsy showed parathyroid tumor, thyroid tumor, and bilateral adrenal pheochromocytomas. |
1965 | Schimke and Hartmann | Described a syndrome of medullary thyroid carcinoma with abundant amyloid stroma and pheochromocytoma [1] |
1966 | Williams | Reported a case of a patient with combination of mucosal neuromas, pheochromocytoma, and medullary thyroid carcinoma |
1968 | Steiner | Introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for multiple endocrine neoplasia type 1 and 'Sipple syndrome' for multiple endocrine neoplasia type 2 |
Meyer and Abdel-Bari | Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells | |
1970 | Kaplan | Suggested that adrenal medulla produces a calcitonin like material[2] |
1974 | Sizemore | Showed that the multiple endocrine neoplasia type 2 category included two groups of patients with medullary thyroid cancer and pheochromocytoma: one with parathyroid disease and a normal appearance (multiple endocrine neoplasia type 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (multiple endocrine neoplasia type 2B) |
1978 | Hamilton | Reported a case of Zollinger-Ellison syndrome in multiple endocrine hyperplasia type 2 |
Cameron | Suggested that medullary carcinoma produces thyrocalcitonin from parafollicular cells[3] | |
1980 | Le Marec | Described a case of congential megacolon in Sipple syndrome[4] |
1989 | Sobol | Proposed that restriction fragment length polymerase is useful in predicting the carrier state of multiple endocrine neoplasia syndrome |
1993 | RET germline mutations were recognized as the causative molecular alterations in multiple endocrine neoplasia type 2 syndromes | |
1998 | MEN1 gene was cloned[5] | |
2000-2001 |
Huang, Koch |
Introduced the 2 hit mechanism for multiple endocrine neoplasia type 2 associated tumors and also described the mechanism of involved in trisomy 10 |
References
- ↑ Schimke RN, Hartmann WH (1965). "Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity". Ann Intern Med. 63 (6): 1027–39. PMID 5844561.
- ↑ Kaplan EL, Arnaud CD, Hill BJ, Peskin GW (1970). "Adrenal medullary calcitonin-like factor: a key to multiple endocrine neoplasia, type 2?". Surgery. 68 (1): 146–9. PMID 10483461.
- ↑ Cameron D, Spiro HM, Landsberg L (1978). "Zollinger-Ellison syndrome with multiple endocrine adenomatosis type II". N Engl J Med. 299 (3): 152–3. doi:10.1056/NEJM197807202990315. PMID 26873.
- ↑ Le Marec B, Roussey M, Cornec A, Calmettes C, Kerisit J, Allanic H (1981). "[Thyroid cancer with amyloid stroma, Sipple's syndrome, congenital megacolon with plexus hyperplasia: one and the same dominant autosomal disease with complete penetrance]". J Genet Hum. 28 (5): 169–74. PMID 7276917.
- ↑ Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9